The 2026 ACC/AHA dyslipidemia guideline retires the 2018 cholesterol document and broadens scope to hypertriglyceridemia and elevated lipoprotein(a). Non-HDL-C and apoB gain ground as secondary targets, LDL goals tighten for high-risk groups, and Lp(a) gets formal standing in risk assessment. Clinicians should anticipate broader lipid panels and more frequent escalation to PCSK9 inhibitors and emerging Lp(a)-lowering therapies.
AIMThe “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.”METHODSA comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.STRUCTUREThe focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
